• Who wouldn’t want the possibility
    of long-term survival?

    In a clinical trial, median* overall survival among patients receiving YERVOY® (ipilimumab) was 10 months. Treatment with YERVOY decreased the risk of death by about one third compared to patients who received the experimental drug.

    About the YERVOY trial. 676 patients with unresectable or metastatic melanoma participated in a study to measure overall survival. These patients were previously treated with one or more of the following: aldesleukin, dacarbazine, temozolomide, foternustine, or carboplatin. The major goal was to measure how long patients lived with YERVOY in combination with the experimental drug compared to the experimental drug alone.

    Patients who received YERVOY alone and patients who took YERVOY plus another experimental drug showed a median overall survival of 10 months. Patients who took the experimental drug alone showeda median overall survival of 6 months.

    Select Safety Information: YERVOY can cause serious side effects in many parts of your body which can lead to death. The most common side effects of YERVOY include: tiredness, diarrhea, itching, and rash.

    These are not all of the possible side effects of YERVOY. If you have any questions about your health or medicines, talk to your healthcare provider. Please see the Important Safety Information below.

    *The median is the middle point at which half of the patients were still alive.

    YERVOY is not approved for patients less than 18 years of age.
      Find out more  
  • You want more than hope.

    With YERVOY® (ipilimumab), you have evidence.

    46% of patients taking YERVOY alone were alive at year 1.

    Estimated percentage, compared with 25% of patients taking an experimental drug alone.


    24% of patients taking YERVOY alone were alive at year 2.

    Estimated percentage, compared with 14% of patients taking an experimental drug alone.

    In a clinical trial, median* overall survival among patients receiving YERVOY was 10 months. Treatment with YERVOY decreased the risk of death by about one third compared to patients who received the experimental drug.

    About the YERVOY trial. 676 patients with unresectable or metastatic melanoma participated in a study to measure overall survival. These patients were previously treated with one or more of the following: aldesleukin, dacarbazine, temozolomide, foternustine, or carboplatin. The major goal was to measure how long patients lived with YERVOY in combination with the experimental drug compared to the experimental drug alone.

    Patients who received YERVOY alone and patients who took YERVOY plus another experimental drug showed a median overall survival of 10 months. Patients who took the experimental drug alone showed a median overall survival of 6 months.

    Select Safety Information: YERVOY can cause serious side effects in many parts of your body which can lead to death. The most common side effects of YERVOY include: tiredness, diarrhea, itching, and rash.

    These are not all of the possible side effects of YERVOY. If you have any questions about your health or medicines, talk to your healthcare provider. Please see the Important Safety Information below.

    *The median is the middle point at which half of the patients were still alive.

      Find out more  
  • Getting YERVOY® (ipilimumab) treatment,or close to someone who is?

    Get YOUR VOYAGE TM, the specialized program
    that supports you throughout treatment.

      Find out more  
  • Just diagnosed withmetastatic melanoma?

    Now get the answers you need to ask your doctor the right questions.
    Get our information package—delivered in just 48 hours.

      Sign up now  
  • Getting YERVOY® (ipilimumab) treatment,or close to someone who is?

    Get YOUR VOYAGE TM, the specialized program
    that supports you throughout treatment.

      Sign up now  
  • JUST DIAGNOSED?

    Get Be Heard. It's Time to Talk Options.
    Delivered in 48 hours.

    Sign up now
  • ALREADY ON YERVOY?

    Get YOUR VOYAGE™ —the program that supports you throughout your treatment.

    Sign up now
  • YOU CAN BE AN INSPIRATION

    Metastatic melanoma changed your life. Your story might change someone else's.

    Tell your story